Watch for FDA feedback on the recently submitted IND for food allergy and the initiation of the Phase 2b/3 CSU trial design. The durability data at 12 weeks off-drug suggests potential for disease modification, which could differentiate CUE-221 vs omalizumab and other competitors.
Price Chart
Executive Summary
Cue Biopharma announced positive topline results from a Phase 2 clinical trial of CUE-221 in chronic spontaneous urticaria (CSU). The primary endpoint (HSS7=0 at week 12) was met with statistical significance at all dose levels, and the key secondary endpoint (UAS7=0) was met at the 4 mg/kg dose. The data showed durable benefit persisting 12 weeks off treatment, with a favorable safety profile, supporting advancement to a Phase 2b/3 registration-enabling trial in CSU and a Phase 2 trial in food allergy.
Key Facts
- Phase 2 trial enrolled 145 participants with moderate-to-severe CSU inadequately controlled on H1-antihistamines.
- Primary endpoint (HSS7=0 at week 12) met at all CUE-221 dose levels: 54% (4 mg/kg), 53% (2 mg/kg), 43% (1 mg/kg) vs 11% placebo (p<0.005 for 4 and 2 mg/kg; p<0.05 for 1 mg/kg).
- Key secondary endpoint (UAS7=0 at week 12) met at 4 mg/kg: 46% vs 11% placebo (p<0.05).
- Complete hives resolution peaked at week 22 (69% at 4 mg/kg) and was maintained for 12 weeks off-drug at week 28 (60% at 4 mg/kg).
- Post-hoc analysis at week 28 showed statistically significant difference vs omalizumab (delta=36%, p<0.05).
- No treatment-related serious adverse events, no anaphylaxis, and only one injection site reaction > grade 1.
- Company plans to initiate a Phase 2b/3 trial in CSU and a Phase 2 trial in food allergy, subject to FDA review.
Financial Impact
No financial figures provided in the filing. The positive Phase 2 data de-risks CUE-221's clinical pathway and supports advancement to registration-enabling trials, which could materially increase the asset's valuation if successful in later-stage studies.
Risk Factors
- Data is from a China-only trial; results may not fully replicate in global populations.
- Phase 2b/3 and Phase 2 trials require additional capital, and the company has a history of losses and limited cash.
- Competitive landscape includes omalizumab, dupilumab, remibrutinib, and barzolvolimab.
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-396094 |
| Document: d21238dex991.htm | 0001193125-26-396094 |
| Document: d21238dex992.htm | 0001193125-26-396094 |
| Document: 0001193125-26-396094-index-headers.html | 0001193125-26-396094 |
| Document: 0001193125-26-396094-index.html | 0001193125-26-396094 |
| Document: 0001193125-26-396094.txt | 0001193125-26-396094 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 14, 2026 11d ago | Insider Cluster | $18.67 $16.71 | ▲ +10.50% | ▲ +9.39% | $18.45 (+1.18%) |
Oct 13, 2026 12d ago | 144 | $18.60 $18.67 | ▲ +0.38% | ▲ +0.09% | $18.45 (−0.81%) |
Oct 8, 2026 18d ago | SC 13G/A | $22.33 $27.66 | ▲ +23.87% | ▲ +23.27% | $18.45 (−17.38%) |
Sep 21, 2026 5w ago | 8-K | $28.27 $30.90 | ▲ +9.30% | ▲ +9.32% | $18.45 (−34.74%) |
Sep 20, 2026 5w ago | Press Release | $28.27 $30.90 | ▲ +9.30% | ▲ +9.32% | $18.45 (−34.74%) |
Aug 21, 2026 9w ago | EFFECT | $23.98 $23.18 | ▲ +3.34% | ▲ +3.04% | $18.45 (+23.06%) |
Aug 17, 2026 10w ago | Insider Cluster | $25.70 $26.28 | ▼ −2.26% | ▼ −2.05% | $18.45 (+28.21%) |
Aug 14, 2026 10w ago | Press Release | $27.64 $25.70 | ▼ −7.02% | ▼ −6.34% | $18.45 (−33.25%) |
Aug 13, 2026 10w ago | 144 | $34.20 $27.64 | ▼ −19.18% | ▼ −18.71% | $18.45 (−46.05%) |
Jul 9, 2026 15w ago | Press Release | $36.78 $30.92 | ▼ −15.93% | ▼ −15.17% | $18.45 (−49.84%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers